Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about lysosomal_membrane: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
| Source | Relation | Type | Str |
|---|---|---|---|
| LAMP1 | stabilizes | gene | 0.00 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Galectin-3 deletion attenuates NLRP3 inflammasome activation | 0.650 | neuroscience | Lysosomal dysfunction and cathepsin leak |
| LAMP-2 replacement therapy prevents lysosomal membrane perme | 0.580 | neuroscience | Lysosomal dysfunction and cathepsin leak |
| Hsp70-based therapy to prevent lysosomal membrane permeabili | 0.570 | neuroscience | Lysosomal dysfunction and cathepsin leak |
| Lysosomal Membrane Repair Enhancement | 0.538 | neurodegeneration | Autophagy-lysosome pathway convergence a |
| Reticulocalbin-2 bridges calcineurin to lysosomal membranes | 0.360 | neurodegeneration | What determines the specificity of calci |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-07 | 7 hypotheses Top: 0.690
neurodegeneration | 2026-04-04 | 15 hypotheses Top: 0.814
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Autophagy Enhancement Drug Screening for Neurodegeneration | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Presymptomatic GRN Carrier Intervention Timing — Biomarker-Guided Ther | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Autophagy and ALS: mechanistic insights and therapeutic implications. [PMID:34057020] | Chua JP, De Calbiac H, Kabashi E, Barmad | Autophagy | 2022 | 2 |
| α-Synuclein aggregates inhibit ESCRT-III through sequestration and collateral de [PMID:40934925] | Sitron CS, Trinkaus VA, Galesic A, Garha | Mol Cell | 2025 | 1 |
| Compromised function of the ESCRT pathway promotes endolysosomal escape of tau s [PMID:31578281] | Chen JJ, Nathaniel DL, Raghavan P, Nelso | J Biol Chem | 2019 | 1 |
| Mislocalization of FTD3-associated mutant CHMP2B to the nucleus of human neurons [PMID:41559796] | ["Jun Y", "Hass E", "Lee S", "Fazzio T", | Acta neuropathologica communic | 2026 | 0 |
| Spatially resolved translational dysregulation in [PMID:41509319] | ["Wu M", "Huang J", "Aryal S", "Farsi Z" | bioRxiv : the preprint server | 2025 | 0 |
| Increased granulovacuolar degeneration in the thalamus and higher neurofibrillar [PMID:40889877] | ["Nagakura A", "Kawakami I", "Kimura A", | Psychiatry and clinical neuros | 2025 | 0 |
| Loss of CHMP2A implicates an ordered assembly of ESCRT-III proteins during cytok [PMID:40928930] | Kamenetsky N, Nachmias D, Khan S, Avinoa | Molecular biology of the cell | 2025 | 0 |
| The multi-dimensional regulatory mechanism of Sirt6 in heart health: From cell d [PMID:40902544] | Zhan S, Guo C, Yan H, Zheng G, Yan D | Biochemical and biophysical re | 2025 | 0 |
| Targeted autophagic clearance of Tau protects against Alzheimer's disease throug [PMID:40963907] | Yoon BH, Kim J, Sengupta S, Park CJ, Ko | Theranostics | 2025 | 0 |
| Pathological α-synuclein elicits granulovacuolar degeneration independent of tau [PMID:40537859] | ["Dues D", "Erb M", "Kasen A", "Vatsa N" | Translational neurodegeneratio | 2025 | 0 |
| Classical swine fever virus recruits ALIX and ESCRT-III to facilitate viral budd [PMID:39998268] | ["Chen J", "Yang H", "Wan M", "Cheng Y", | mBio | 2025 | 0 |
| The Ku80-p53-SIRT1 axis in DNA damage response contributes to sporadic and famil [PMID:41422089] | ["Jun Y", "Lee S", "Almeida S", "Freude | Nature communications | 2025 | 0 |
| Truncation mutation of CHMP2B disrupts late endosome function but reduces TDP-43 [PMID:40316175] | ["Iguchi Y", "Takahashi Y", "Li J", "Ama | Neurochemistry international | 2025 | 0 |
| The expanding repertoire of ESCRT functions in cell biology and disease. [PMID:40562928] | Hurley JH, Coyne AN, Miączyńska M, Stenm | Nature | 2025 | 0 |
| Methylation of ESCRT-III components regulates the timing of cytokinetic abscissi [PMID:38740816] | Richard A, Berthelet J, Judith D, Advedi | Nature communications | 2024 | 0 |
| Extracellular NCOA4 is a mediator of septic death by activating the AGER-NFKB pa [PMID:38916095] | ["Liu J", "Wang Y", "Zeng L", "Yu C", "K | Autophagy | 2024 | 0 |
| The spectrum of neurodevelopmental, neuromuscular and neurodegenerative disorder [PMID:34130600] | Deneubourg C, Ramm M, Smith LJ, Baron O, | Autophagy | 2022 | 0 |
| Lessons learned from CHMP2B, implications for frontotemporal dementia and amyotr [PMID:33144171] | Ugbode C, West RJH | Neurobiology of disease | 2021 | 0 |
| Expression of mutant CHMP2B linked to neurodegeneration in humans disrupts circa [PMID:32123847] | ["Lee D", "Zheng X", "Shigemori K", "Kra | FASEB bioAdvances | 2019 | 0 |
| Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced m [PMID:29400714] | Shi Y, Lin S, Staats KA, Li Y, Chang WH, | Nature medicine | 2018 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.61 · 2026-04-21
closed · Rounds: 4 · Score: 0.90 · 2026-04-12
closed · Rounds: 3 · Score: 0.95 · 2026-04-04
Hypotheses and analyses mentioning lysosomal_membrane in their description or question text
No additional research found